Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tesevatinib - Exelixis/Symphony Evolution

Drug Profile

Tesevatinib - Exelixis/Symphony Evolution

Alternative Names: KD-019; KD-020; Tesevatinib tosylate; XL-647

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Exelixis; Kadmon Pharmaceuticals
  • Class Amines; Antineoplastics; Cyclopentanes; Pyrroles; Quinazolines; Small molecules; Urologics
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal recessive polycystic kidney disease; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Autosomal dominant polycystic kidney disease; Glioblastoma
  • Phase I Autosomal recessive polycystic kidney disease
  • No development reported Breast cancer; Liver cancer; Prostate cancer

Most Recent Events

  • 30 Sep 2019 Kadmon Corporation completes a phase-I clinical trials in Autosomal-recessive polycystic kidney disease (In children) in USA (PO, suspension) (NCT03096080)
  • 08 Feb 2019 Kadmon completes a phase I/II trial in Autosomal dominant polycystic kidney disease (In adults) in USA (NCT01559363)
  • 28 Aug 2018 Kadmon completes a phase II trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02616393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top